$USNU
Elite Health Systems Inc.

2020 Q4 Form 10-K Financial Statement

#000114036121011976 Filed on April 07, 2021

View on sec.gov

Income Statement

Concept 2020 Q4 2019 Q4 2019
Revenue $1.168M $746.0K $3.070M
YoY Change 56.57% 17.48% -10.34%
Cost Of Revenue $85.00K $101.0K $350.0K
YoY Change -15.84% 27.85% -73.9%
Gross Profit $1.083M $645.0K $2.720M
YoY Change 67.91% 16.01% 30.58%
Gross Profit Margin 92.72% 86.46% 88.6%
Selling, General & Admin $256.0K $270.0K $1.230M
YoY Change -5.19% -23.94% -4.58%
% of Gross Profit 23.64% 41.86% 45.22%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $0.00 $0.00
YoY Change -100.0%
% of Gross Profit 0.0% 0.0%
Operating Expenses $256.0K $270.0K $1.580M
YoY Change -5.19% -73.48% -52.02%
Operating Profit $827.0K $375.0K $1.490M
YoY Change 120.53% -181.17% 1037.4%
Interest Expense -$503.0K -$569.0K $91.00K
YoY Change -11.6% 54.62% -19.47%
% of Operating Profit -60.82% -151.73% 6.11%
Other Income/Expense, Net
YoY Change
Pretax Income $324.0K -$194.0K $151.0K
YoY Change -267.01% -76.63% -124.63%
Income Tax $175.0K -$94.00K $9.000K
% Of Pretax Income 54.01% 5.96%
Net Earnings $149.0K -$100.0K $142.0K
YoY Change -249.0% -77.27% -133.73%
Net Earnings / Revenue 12.76% -13.4% 4.63%
Basic Earnings Per Share
Diluted Earnings Per Share $19.12K -$12.83K $18.22K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q4 2019 Q4 2019
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.030M $1.335M $1.335M
YoY Change 52.06% -12.11% -12.11%
Cash & Equivalents $2.030M $1.335M $1.335M
Short-Term Investments
Other Short-Term Assets $99.00K $102.0K $102.0K
YoY Change -2.94% -33.77% -33.77%
Inventory
Prepaid Expenses
Receivables $346.0K $356.0K $356.0K
Other Receivables $532.0K $888.0K $888.0K
Total Short-Term Assets $3.007M $2.681M $2.681M
YoY Change 12.16% -33.98% -33.98%
LONG-TERM ASSETS
Property, Plant & Equipment $94.00K $128.0K $128.0K
YoY Change -26.56%
Goodwill $0.00
YoY Change
Intangibles
YoY Change
Long-Term Investments $160.0K $179.0K $179.0K
YoY Change -10.61% 6.55% 6.55%
Other Assets $1.072M $2.188M $1.439M
YoY Change -51.01% 2.05%
Total Long-Term Assets $1.166M $2.316M $2.316M
YoY Change -49.65% 8.02% 8.02%
TOTAL ASSETS
Total Short-Term Assets $3.007M $2.681M $2.681M
Total Long-Term Assets $1.166M $2.316M $2.316M
Total Assets $4.173M $4.997M $4.997M
YoY Change -16.49% -19.47% -19.47%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $255.0K $255.0K
YoY Change 12.33% 12.33%
Accrued Expenses $40.00K $36.00K $36.00K
YoY Change 11.11%
Deferred Revenue $0.00 $226.0K
YoY Change -100.0% -11.37%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $89.00K $901.0K $901.0K
YoY Change -90.12% -35.6% -35.6%
Total Short-Term Liabilities $410.0K $1.638M $1.638M
YoY Change -74.97% -12.92% -12.92%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $89.00K $89.00K
YoY Change -100.0% -90.99% -90.99%
Other Long-Term Liabilities $77.00K $117.0K $117.0K
YoY Change -34.19% 963.64% 963.64%
Total Long-Term Liabilities $77.00K $206.0K $206.0K
YoY Change -62.62% -79.38% -79.38%
TOTAL LIABILITIES
Total Short-Term Liabilities $410.0K $1.638M $1.638M
Total Long-Term Liabilities $77.00K $206.0K $206.0K
Total Liabilities $487.0K $1.844M $1.844M
YoY Change -73.59% -42.27% -42.27%
SHAREHOLDERS EQUITY
Retained Earnings $508.0K -$25.00K
YoY Change -2132.0% -85.03%
Common Stock $3.178M $3.178M
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.686M $3.153M $3.153M
YoY Change
Total Liabilities & Shareholders Equity $4.173M $4.997M $4.997M
YoY Change -16.49% -19.47% -19.47%

Cashflow Statement

Concept 2020 Q4 2019 Q4 2019
OPERATING ACTIVITIES
Net Income $149.0K -$100.0K $142.0K
YoY Change -249.0% -77.27% -133.73%
Depreciation, Depletion And Amortization $0.00 $0.00
YoY Change -100.0%
Cash From Operating Activities $595.0K $466.0K $1.547M
YoY Change 27.68% -2.51% -32.39%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $22.00K -$160.0K -$334.0K
YoY Change -113.75% -23.81% -81.43%
Cash From Investing Activities $22.00K -$160.0K -$334.0K
YoY Change -113.75% -23.81% -85.9%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -87.00K -363.0K -1.397M
YoY Change -76.03% 0.0% 28.87%
NET CHANGE
Cash From Operating Activities 595.0K 466.0K 1.547M
Cash From Investing Activities 22.00K -160.0K -334.0K
Cash From Financing Activities -87.00K -363.0K -1.397M
Net Change In Cash 530.0K -57.00K -184.0K
YoY Change -1029.82% -40.0% -84.21%
FREE CASH FLOW
Cash From Operating Activities $595.0K $466.0K $1.547M
Capital Expenditures $0.00 $0.00
Free Cash Flow $466.0K $1.547M
YoY Change -2.51% -45.87%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019 us-gaap Advertising Expense
AdvertisingExpense
0
CY2020 us-gaap Advertising Expense
AdvertisingExpense
0
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
3100000
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0
CY2019Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
255000
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
170000
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
356000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
346000
CY2019Q4 us-gaap Accounts Receivable Related Parties Noncurrent
AccountsReceivableRelatedPartiesNoncurrent
1422000
CY2020Q4 us-gaap Accounts Receivable Related Parties Noncurrent
AccountsReceivableRelatedPartiesNoncurrent
912000
CY2020Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
111000
CY2019Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
220000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
3100000
CY2019Q4 us-gaap Asset Retirement Obligation
AssetRetirementObligation
0
CY2020Q4 us-gaap Asset Retirement Obligation
AssetRetirementObligation
0
CY2020Q4 us-gaap Assets
Assets
4173000
CY2019Q4 us-gaap Assets
Assets
4997000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
2681000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
3007000
CY2019 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
176000
CY2020 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
0
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2030000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1335000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-184000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
695000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1519000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1335000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2030000
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7792185
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7792185
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
25000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
25000000
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7792185
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7792185
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
78000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
78000
CY2020 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"><tr><td style="width: 27pt; vertical-align: top; font-weight: bold;">[16]</td><td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-weight: bold;">Credit risk:</div></td></tr></table><div><font style="font-size: 10pt;"></font></div><div><font style="font-size: 10pt;"><br /></font></div><div><font style="font-size: 10pt;"></font></div><div style="text-align: justify; margin-left: 25.2pt; font-size: 10pt;">At times, the Company may have cash and cash equivalents at a financial institution in excess of insured limits. The Company places its cash and cash equivalents with high credit quality financial institutions whose credit ratings are monitored by management to minimize credit risk. Accounts receivable consist of amounts due from the medical centers.&#160; Historically, credit losses on accounts receivable have not been significant. At December 31, 2020 and 2019, substantially all of the Company&#8217;s accounts receivable were due from one customer, NYU.</div></div>
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
0
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
226000
CY2015Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
20000
CY2017Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
26000
CY2019 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
271000
CY2020 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
211000
CY2019 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
69000
CY2020 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
95000
CY2020 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
306000
CY2019 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
340000
CY2020Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
0
CY2019Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
17000
CY2020 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
12000
CY2019 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-288000
CY2019 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-331000
CY2020 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
17000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
708000
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
587000
CY2019 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-43000
CY2020 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
5000
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2019Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
17000
CY2019Q4 us-gaap Deferred Tax Assets Equity Method Investments
DeferredTaxAssetsEquityMethodInvestments
569000
CY2020Q4 us-gaap Deferred Tax Assets Equity Method Investments
DeferredTaxAssetsEquityMethodInvestments
561000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
0
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
34000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
0
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
79000
CY2020Q4 us-gaap Deferred Tax Liabilities Tax Deferred Income
DeferredTaxLiabilitiesTaxDeferredIncome
634000
CY2019Q4 us-gaap Deferred Tax Liabilities Tax Deferred Income
DeferredTaxLiabilitiesTaxDeferredIncome
526000
CY2019 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
14000
CY2020 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
14000
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.07
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.02
CY2020 us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
176000
CY2019 us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
76000
CY2019Q4 us-gaap Equity Method Investments
EquityMethodInvestments
179000
CY2020Q4 us-gaap Equity Method Investments
EquityMethodInvestments
160000
CY2020Q4 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
0
CY2020Q4 us-gaap Finance Lease Liability
FinanceLeaseLiability
89000
CY2020Q4 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
1000
CY2020Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
89000
CY2019Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
901000
CY2020Q4 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
0
CY2020Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
0
CY2019Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
89000
CY2020Q4 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
90000
CY2020Q4 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
90000
CY2020Q4 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.05850
CY2019 us-gaap Health Care Organization Expenses Net
HealthCareOrganizationExpensesNet
350000
CY2020 us-gaap Health Care Organization Expenses Net
HealthCareOrganizationExpensesNet
361000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
151000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
856000
CY2020 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-809000
CY2019 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-1386000
CY2019 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
32000
CY2020 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
180000
CY2019 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
0
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
79000
CY2019 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
-26000
CY2020 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
-4000
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
9000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
323000
CY2020 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
52000
CY2019 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
10000
CY2019 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
-7000
CY2020 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
16000
CY2019 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
158000
CY2020 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
419000
CY2019 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-178000
CY2020 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
6000
CY2020 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-226000
CY2019 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-29000
CY2020 us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
0
CY2019 us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
200000
CY2020 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-85000
CY2019 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
43000
CY2019 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
38000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
106000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
66000
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-10000
CY2019 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
-321000
CY2020 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
109000
CY2020 us-gaap Interest Expense
InterestExpense
25000
CY2019 us-gaap Interest Expense
InterestExpense
91000
CY2019 us-gaap Interest Paid Net
InterestPaidNet
94000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
115000
CY2020 us-gaap Interest Paid Net
InterestPaidNet
25000
CY2020 us-gaap Investment Income Interest
InvestmentIncomeInterest
3000
CY2019 us-gaap Investment Income Interest
InvestmentIncomeInterest
6000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
24000
CY2020Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
9000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
46000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
45000
CY2019 us-gaap Lease Cost
LeaseCost
0
CY2020 us-gaap Lease Cost
LeaseCost
7000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4997000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4173000
CY2020Q4 us-gaap Liabilities
Liabilities
487000
CY2019Q4 us-gaap Liabilities
Liabilities
1844000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1638000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
410000
CY2020 us-gaap Malpractice Insurance Annual Coverage Limit
MalpracticeInsuranceAnnualCoverageLimit
3000000
CY2020 us-gaap Nature Of Operations
NatureOfOperations
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-weight: bold;">Note A &#8211; Organization and Business</div><div><br /></div><div style="text-align: justify;">U.S. NeuroSurgical Holdings, Inc. owns and operates, through its wholly-owned subsidiaries, stereotactic radiosurgery centers, utilizing gamma knife technology, and holds other interests in radiological treatment facilities.&#160; As used herein, unless the context indicates otherwise, the term &#8220;Company&#8221;, &#8220;Registrant&#8221; and &#8220;Holdings&#8221; means U.S. NeuroSurgical Holdings, Inc. and its wholly-owned subsidiary, U.S. NeuroSurgical, Inc. (&#8220;USN&#8221;), and the wholly-owned subsidiaries of USN, U.S. NeuroSurgical Physics, Inc. and USN Corona, Inc.</div><div><br /></div><div style="text-align: justify;">U.S. NeuroSurgical, Inc. a Delaware corporation, was organized in July 1993 for the purpose of owning and operating stereotactic radiosurgery centers, utilizing the gamma knife technology.&#160; USN holds an interest in one gamma knife center on the premises of New York University Medical Center (&#8220;NYU&#8221;) in New York, New York.&#160; Management continues to explore opportunities to organize and participate in additional gamma knife centers.&#160; USN&#8217;s business strategy is to provide a mechanism whereby hospitals, physicians, and patients can have access to gamma knife treatment capability, a high capital cost item.&#160; USN provides the gamma knife to medical facilities on a &#8220;cost per treatment&#8221; basis.&#160; USN holds an interest in the gamma knife unit and is reimbursed by the facility where it is housed, based on utilization.</div><div><br /></div><div style="text-align: justify;">During the fourth quarter of 2007, USN formed a wholly-owned subsidiary, USN Corona, Inc. (&#8220;USNC&#8221;), to carry investments in Corona Gamma Knife, LLC and NeuroPartners, LLC. Those investments were formed to develop and manage a gamma knife center at San Antonio Regional Hospital in Upland, California. (See Note C[1])</div><div><br /></div><div style="text-align: justify;">During 2010, through the formation of a joint venture, in which it has a noncontrolling interest, the Company expanded its market strategy to include opportunities to develop cancer centers featuring radiation therapy. These centers utilize linear accelerators with IMRT (Intensity Modulated Radiation Therapy) and IGRT (Image Guided Radiation Therapy) capabilities. In 2010, the Company formed Florida Oncology Partners, LLC (&#8220;FOP&#8221;) in partnership with local physicians and other investors. USNC owns a 24% interest in the venture. FOP&#8217;s first center was located in Miami, Florida and opened in the second quarter of 2011. The Company entered into an arrangement to sell the center to 21<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">st</sup> Century Oncology in December 2015. The sale has not occurred as of December 31, 2020. (See Note C[2])</div><div><br /></div><div style="text-align: justify;">During 2011, the Company participated in the formation of Boca Oncology Partners RE, LLC (&#8220;BOPRE&#8221;), for the purpose of acquiring an interest in Boca West, IMP, LLC, (&#8220;Boca West, IMP&#8221;) which owns a medical office building. (See Note C[3]).</div><div><br /></div><div style="text-align: justify;">In 2015, Medical Oncology Partners LLC (&#8220;MOP&#8221;), was formed in partnership with local physicians and other investors. MOP was established to acquire a 100% equity interest in United Oncology Medical Associates of Florida, LLC (&#8220;UOMA&#8221;). USNC was not a member of MOP at the time of its formation, as it was not able to participate in MOP&#8217;s formation due to the fact that USNC was not a physician. An application was filed for a waiver and on December 22, 2016, USNC was cleared to become a part owner of MOP. USNC currently owns 35.83% of MOP. (See Note C[4])</div><div><br /></div><div style="text-align: justify;">On September 3, 2015, pursuant to the Agreement and Plan of Reorganization (the &#8220;Merger Agreement&#8221;), dated as of September 3, 2015, by and among USN, Holdings and U.S. NeuroSurgical Merger Sub, Inc. (&#8220;Merger Sub&#8221;), the Company adopted a new holding company organizational structure whereby USN is now a wholly owned subsidiary of Holdings. This structure did not result in any changes to the assets or operations of the Company, but management believes that it will create a more flexible framework for possible future transactions and organizational and operational adjustments.</div><div style="text-align: justify;"><br /></div><div style="text-align: justify;">The holding company organizational structure was effected by a merger (the &#8220;Merger&#8221;) conducted pursuant to Section 251(g) of the Delaware General Corporation Law (the &#8220;DGCL&#8221;), which provides for the formation of a holding company structure without a vote of the stockholders of the constituent corporations.&#160; Because the holding company organizational structure occurred at the parent company level, the remainder of the Company&#8217;s subsidiaries, operations and customers were not affected by this transaction.</div><div style="text-align: justify;"><br /></div><div style="text-align: justify;">In order to effect the Merger, USN formed Holdings as its wholly owned subsidiary and Holdings formed Merger Sub as its wholly owned subsidiary.&#160; Under the terms of the Merger Agreement, Merger Sub merged with and into USN, with USN surviving the merger and becoming a direct, wholly owned subsidiary of Holdings.&#160;&#160; Immediately prior to the Merger, Holdings had no assets, liabilities or operations.</div><div><br /></div><div style="text-align: justify;">Pursuant to the Merger Agreement, all of the outstanding capital stock of USN was converted, on a share for share basis, into capital stock of Holdings.&#160; As a result, each former stockholder of USN became the owner of an identical number of shares of capital stock of Holdings, evidencing the same proportional interests in Holdings and having the same designations, rights, powers and preferences, qualifications, limitations and restrictions, as those that the stockholder held in USN.</div><div style="text-align: justify;"><br /></div><div style="text-align: justify;">Following the Merger, Holdings&#8217; common stock continued to trade on the over-the-counter market and continued to be quoted on the OTC Markets under the same symbol, &#8220;USNU.&#8221;&#160; The conversion of shares of capital stock under the Merger Agreement occurred without an exchange of physical certificates.&#160; Accordingly, physical certificates formerly representing shares of outstanding capital stock of USN are deemed to represent the same number of shares of capital stock of Holdings.</div><div style="text-align: justify;"><br /></div><div style="text-align: justify;">Pursuant to Section 251(g) of the DGCL, the provisions of the certificate of incorporation and bylaws of Holdings are substantially identical to those of USN prior to the date on which the Merger Agreement took effect.&#160; The authorized capital stock of Holdings, the designations, rights, powers and preferences of such capital stock, and the qualifications, limitations and restrictions thereof are also substantially identical to those of the capital stock of USN immediately prior to the date of the Merger.&#160; Further, the directors and executive officers of Holdings are the same individuals who were directors and executive officers, respectively, of USN immediately prior to the date of the Merger.</div><div><br /></div><div style="text-align: justify;">Late in 2016, FOP took initial steps toward the development of a new radiation therapy center in Homestead, Florida.&#160; However, late in the third quarter of 2017, it was determined that the business opportunity at this new location should be pursued by a different investor group, and FOP arranged to sell the opportunity to this group.&#160; CB Oncology Partners, LLC (&#8220;CBOP&#8221;) was organized on September 1, 2017 to acquire the assets and rights in this new center from FOP. USNC owns a 28.58% interest in CBOP.</div><div><br /></div><div style="text-align: justify;">In June 2017, FOP entered into an agreement with a third-party owner of a radiation therapy center located in Miami, Florida, whereby FOP took over the operation of the center effective September 22, 2017, for a ten-year initial term, and up to three additional terms of five years each. FOP abandoned its operations at this radiation center on June 28, 2019 due to continued losses at the site and lack of success in good faith efforts to renegotiate the agreement after several months of discussion.&#160; FOP could be considered in default of the agreement and the third-party owner could pursue action against FOP.&#160; Due to abandoning the operations of the Miami center as well as continued working capital deficits, FOP&#8217;s ability to continue as a going concern will require FOP to restructure debt, raise new capital, and successfully settle the agreement at the center in Miami, Florida. Since these plans are preliminary and have not been approved at this date, there is substantial doubt about FOP&#8217;s ability to continue as a going concern within the next twelve months from the date these consolidated financial statements are available to be issued.</div><div><br /></div><div style="text-align: justify;">The Company, through the formation of noncontrolling interests in unconsolidated joint ventures, is currently exploring other opportunities for the establishment of cancer centers using IMRT and/or IGRT in Florida and other parts of the U.S.</div><div style="text-align: justify;"><br /></div><div style="text-align: justify;">The recent outbreak of the novel coronavirus COVID-19 has spread across the globe and has been declared a public health emergency by the World Health Organization and a National Emergency by the President of the United States.&#160; Most states and municipalities in the U.S., including New York, California, and Florida, have taken aggressive measures to reduce the spread of the disease, including limiting non-essential gatherings of people, ceasing all non-essential travel, ordering certain businesses and government agencies to cease non-essential operations at physical locations and issuing &#8220;shelter-in-place&#8221; orders, which direct individuals to shelter at their places of residence (subject to limited exceptions).&#160; Across the healthcare industry, resources are being prioritized for the treatment and management of the outbreak.&#160; Consequently, there are delays in delivering Gamma Knife and other radiation therapy treatments.&#160; In addition, the COVID-19 pandemic poses the risk that the Company and its employees, contractors, customers, government and third party payors and others may be prevented from conducting business activities for an indefinite period of time, including due to spread of the disease within these groups or due to shutdowns that have been and may continue to be requested or mandated by governmental authorities.</div><div style="text-align: justify;"><br /></div><div style="text-align: justify;">While the healthcare treatments that are provided by the Company are generally critical to the well-being of the patients it serves, a&#160; sustained COVID-19 pandemic, and continued measures by the government and industry to contain the pandemic, could negatively impact results for the following reasons: (i) operations at medical facilities, including those operated by the Company, could be subject to reduced operation or prolonged closure; (ii) medical facilities may defer Gamma Knife and other cancer therapy treatments for non-urgent patient cases in order to allocate resources to the care of patients with COVID-19; (iii) patients may defer or cancel treatments due to real or perceived concerns about the potential spread of COVID-19 in a medical facility setting; (iv) the outbreak could materially impact operations for a sustained period of time due to the current travel bans and restrictions, quarantines, shelter-in-place orders and shutdowns; and/or (v) members of the Company&#8217;s workforce may become ill or have family members who are ill and are absent as a result, or they may elect not to come to work due to the illness affecting others in our office or facilities.</div><div><br /></div><div style="text-align: justify;">The occurrence of any of the foregoing events could have a material adverse effect on our business, financial condition and results of operations. The COVID-19 outbreak and mitigation measures have had and may continue to have an adverse impact on global economic conditions which could have an adverse effect on our business and financial condition.&#160; The extent to which the COVID-19 outbreak impacts our results will depend on future developments that are highly uncertain and cannot be predicted, including new information that may emerge concerning the severity of the virus and the actions to contain its impact. Although the Company&#8217;s contract with its only customer ended in March 2021, the Company is actively seeking new business ventures and believes that its cash reserves, which are in excess of $2 million at December 31, 2020, will allow the Company the opportunity do so.&#160; Such plans include possible new operations or extensions of its activities in Florida and California, where it has established working relationships with physician groups, hospitals and other organizations.&#160; In addition to these activities, the Company has been exploring possible combinations with other existing businesses that would create a larger operating entity that would better justify the expenses involved in continuing as an independent publicly traded company.</div></div>
CY2019Q4 us-gaap Net Investment In Lease Noncurrent
NetInvestmentInLeaseNoncurrent
532000
CY2020Q4 us-gaap Net Investment In Lease Noncurrent
NetInvestmentInLeaseNoncurrent
0
CY2019Q4 us-gaap Net Investment In Lease Current
NetInvestmentInLeaseCurrent
888000
CY2020Q4 us-gaap Net Investment In Lease Current
NetInvestmentInLeaseCurrent
532000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1547000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1117000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
533000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
142000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
479000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-334000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1397000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-901000
CY2019Q4 us-gaap Notes And Loans Receivable Net Noncurrent
NotesAndLoansReceivableNetNoncurrent
38000
CY2020Q4 us-gaap Notes And Loans Receivable Net Noncurrent
NotesAndLoansReceivableNetNoncurrent
0
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.05850
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
106000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
40000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
36000
CY2019 us-gaap Operating Expenses
OperatingExpenses
1580000
CY2020 us-gaap Operating Expenses
OperatingExpenses
1558000
CY2020 us-gaap Operating Lease Expense
OperatingLeaseExpense
42000
CY2019 us-gaap Operating Lease Expense
OperatingLeaseExpense
43000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
94000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
128000
CY2019 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
33000
CY2020 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
34000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
1490000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
1615000
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
99000
CY2019Q4 us-gaap Other Assets Current
OtherAssetsCurrent
102000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1072000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2188000
CY2020 us-gaap Payments For Proceeds From Loans Receivable
PaymentsForProceedsFromLoansReceivable
-175000
CY2019 us-gaap Payments For Proceeds From Loans Receivable
PaymentsForProceedsFromLoansReceivable
-434000
CY2020 us-gaap Payments For Advance To Affiliate
PaymentsForAdvanceToAffiliate
459000
CY2019 us-gaap Payments For Advance To Affiliate
PaymentsForAdvanceToAffiliate
1572000
CY2019 us-gaap Payments To Acquire Businesses And Interest In Affiliates
PaymentsToAcquireBusinessesAndInterestInAffiliates
25000
CY2020 us-gaap Payments To Acquire Businesses And Interest In Affiliates
PaymentsToAcquireBusinessesAndInterestInAffiliates
125000
CY2019 us-gaap Proceeds From Collection Of Lease Receivables
ProceedsFromCollectionOfLeaseReceivables
829000
CY2020 us-gaap Proceeds From Collection Of Lease Receivables
ProceedsFromCollectionOfLeaseReceivables
888000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
128000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
94000
CY2019 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
161000
CY2020 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2019 us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
1397000
CY2020 us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
901000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-25000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
508000
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3173000
CY2020 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3070000
CY2018Q3 us-gaap Sales Type Lease Lease Receivable
SalesTypeLeaseLeaseReceivable
2447000
CY2020 us-gaap Sales Type Lease Interest Income
SalesTypeLeaseInterestIncome
72000
CY2019 us-gaap Sales Type Lease Interest Income
SalesTypeLeaseInterestIncome
132000
CY2019 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1230000
CY2020 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1197000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
3686000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
3153000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
3011000
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"><tr><td style="width: 27pt; vertical-align: top; font-weight: bold;">[14]</td><td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-weight: bold;">Estimates and assumptions:</div></td></tr></table><div><font style="font-size: 10pt;"></font></div><div><font style="font-size: 10pt;"><br /></font></div><div><font style="font-size: 10pt;"></font></div><div style="text-align: justify; margin-left: 27pt; font-size: 10pt;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.&#160; Actual results could differ from those estimates.</div></div>
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
7792185
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
7792185
CY2019 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
0
CY2020 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
0
CY2020 dei Amendment Flag
AmendmentFlag
false
CY2020 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020 dei Document Period End Date
DocumentPeriodEndDate
2020-12-31
CY2020 dei Entity Address State Or Province
EntityAddressStateOrProvince
MD
CY2020 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2020 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2020 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020Q2 dei Entity Public Float
EntityPublicFloat
811000
CY2020 dei Entity Registrant Name
EntityRegistrantName
U.S. NeuroSurgical Holdings, Inc.
CY2020 dei Entity Central Index Key
EntityCentralIndexKey
0001089815
CY2021Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
7792185
CY2020 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2020 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2020 dei Document Type
DocumentType
10-K
CY2020 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020 dei Entity Shell Company
EntityShellCompany
false
CY2020 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2020 dei Entity Small Business
EntitySmallBusiness
true
CY2020 usnu Increase Decrease In Operating Lease Right Of Use Liability
IncreaseDecreaseInOperatingLeaseRightOfUseLiability
36000
CY2019 usnu Increase Decrease In Operating Lease Right Of Use Liability
IncreaseDecreaseInOperatingLeaseRightOfUseLiability
34000
CY2019 usnu Income Loss From Equity Method Investments Net
IncomeLossFromEquityMethodInvestmentsNet
-1386000
CY2020 usnu Income Loss From Equity Method Investments Net
IncomeLossFromEquityMethodInvestmentsNet
-809000
CY2020 usnu Accrued Distribution Equity Method Investment
AccruedDistributionEquityMethodInvestment
0
CY2019 usnu Accrued Distribution Equity Method Investment
AccruedDistributionEquityMethodInvestment
20000
CY2020 usnu Conversion Of Advance To Unconsolidated Entity In Lieu Of Cash Payment For Capital Contribution
ConversionOfAdvanceToUnconsolidatedEntityInLieuOfCashPaymentForCapitalContribution
121000
CY2019 usnu Conversion Of Advance To Unconsolidated Entity In Lieu Of Cash Payment For Capital Contribution
ConversionOfAdvanceToUnconsolidatedEntityInLieuOfCashPaymentForCapitalContribution
0
CY2019 usnu Operating Leases Deferred Rent Derecognition
OperatingLeasesDeferredRentDerecognition
15000
CY2020 usnu Operating Leases Deferred Rent Derecognition
OperatingLeasesDeferredRentDerecognition
0
CY2019Q4 usnu Total Leased Assets Operating And Financing
TotalLeasedAssetsOperatingAndFinancing
1548000
CY2020Q4 usnu Total Leased Assets Operating And Financing
TotalLeasedAssetsOperatingAndFinancing
626000
CY2019Q4 usnu Total Lease Liabilities Operating And Finance
TotalLeaseLiabilitiesOperatingAndFinance
1132000
CY2020Q4 usnu Total Lease Liabilities Operating And Finance
TotalLeaseLiabilitiesOperatingAndFinance
195000
CY2020 usnu Renovation Installation And Operation Agreement Period
RenovationInstallationAndOperationAgreementPeriod
P14Y
CY2020Q4 usnu Amount Of Guarantee Obligations Noncurrent
AmountOfGuaranteeObligationsNoncurrent
11000
CY2019Q4 usnu Amount Of Guarantee Obligations Noncurrent
AmountOfGuaranteeObligationsNoncurrent
11000
CY2019Q4 usnu Deferred Tax Liabilities Excess Of Depreciation Over Book Depreciation
DeferredTaxLiabilitiesExcessOfDepreciationOverBookDepreciation
44000
CY2020Q4 usnu Deferred Tax Liabilities Excess Of Depreciation Over Book Depreciation
DeferredTaxLiabilitiesExcessOfDepreciationOverBookDepreciation
0
CY2019Q4 usnu Deferred Tax Liability Net Effect Of Conversion From Accrual Basis Of Accounting To Cash Basis
DeferredTaxLiabilityNetEffectOfConversionFromAccrualBasisOfAccountingToCashBasis
0
CY2020Q4 usnu Deferred Tax Liability Net Effect Of Conversion From Accrual Basis Of Accounting To Cash Basis
DeferredTaxLiabilityNetEffectOfConversionFromAccrualBasisOfAccountingToCashBasis
74000
CY2019Q4 usnu Deferred Tax Assets Excess Of Depreciation Over Tax Depreciation
DeferredTaxAssetsExcessOfDepreciationOverTaxDepreciation
0
CY2020Q4 usnu Deferred Tax Assets Excess Of Depreciation Over Tax Depreciation
DeferredTaxAssetsExcessOfDepreciationOverTaxDepreciation
192000
CY2019Q4 usnu Deferred Tax Assets Net Effect Of Conversion From Accrual Basis Of Accounting To Cash Basis
DeferredTaxAssetsNetEffectOfConversionFromAccrualBasisOfAccountingToCashBasis
18000
CY2020Q4 usnu Deferred Tax Assets Net Effect Of Conversion From Accrual Basis Of Accounting To Cash Basis
DeferredTaxAssetsNetEffectOfConversionFromAccrualBasisOfAccountingToCashBasis
0
CY2020Q4 usnu Estimated Cost To Remove The Gamma Knife Agreement
EstimatedCostToRemoveTheGammaKnifeAgreement
620000
CY2020 usnu Warranty Term Of Maintenance Agreement
WarrantyTermOfMaintenanceAgreement
P1Y
CY2020 usnu Maintenance Agreement
MaintenanceAgreement
P5Y

Files In Submission

Name View Source Status
0001140361-21-011976-index-headers.html Edgar Link pending
0001140361-21-011976-index.html Edgar Link pending
0001140361-21-011976.txt Edgar Link pending
0001140361-21-011976-xbrl.zip Edgar Link pending
brhc10022476_10k.htm Edgar Link pending
brhc10022476_ex31-1.htm Edgar Link pending
brhc10022476_ex32-1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
usnu-20201231.xml Edgar Link completed
usnu-20201231.xsd Edgar Link pending
usnu-20201231_cal.xml Edgar Link unprocessable
usnu-20201231_def.xml Edgar Link unprocessable
usnu-20201231_lab.xml Edgar Link unprocessable
usnu-20201231_pre.xml Edgar Link unprocessable